Key result
The CAMI-NSTEMI risk score, incorporating 9 clinical variables, accurately predicted 24-month all-cause mortality in NSTEMI survivors with a C-statistic of 0.83.
Why the study?
Current risk stratification efforts have focused on short-term risk prediction after discharge, leaving a need for a risk score to predict 24-month mortality risk in survivors of NSTEMI.
Does a 9-variable risk score accurately predict 24-month mortality risk in patients who survive NSTEMI?
Cohort (n=5,509)
Yes
Does a 9-variable risk score accurately predict 24-month mortality risk in patients who survive NSTEMI?
A practical 9-variable risk score demonstrates high discriminative ability (C-statistic 0.83) for predicting 24-month all-cause mortality in NSTEMI survivors.
BACKGROUND: Risk stratification of patients with non-ST-segment elevation myocardial infarction (NSTEMI) is important in terms of treatment strategy selection. Current efforts have focused on short-term risk prediction after discharge, but we aimed to establish a risk score to predict the 24-month mortality risk in survivors of NSTEMI. METHODS AND RESULTS: A total of 5,509 patients diagnosed with NSTEMI between January 2013 and September 2014 were included. Primary endpoint was all-cause death at 24 months. A multivariable Cox regression model was used to establish a practical risk score based on independent risk factors of death. The risk score included 9 variables: age, body mass index, left ventricular ejection fraction, reperfusion therapy during hospitalization, Killip classification, prescription of diuretics at discharge, heart rate, and hemoglobin and creatinine levels. The C-statistics for the risk model were 0.83 (95% confidence interval [CI]: 0.81-0.85) and 0.83 (95% CI: 0.79-0.86) in the development and validation cohorts, respectively. Mortality risk increased significantly across groups: 1.34% in the low-risk group (score: 0-58), 5.40% in intermediate group (score: 59-93), and 23.87% in high-risk group (score: ≥94). CONCLUSIONS: The current study established and validated a practical risk score based on 9 variables to predict 24-month mortality risk in patients who survive NSTEMI. This score could help identify patients who are at high risk for future adverse events who may benefit from good adherence to guideline-recommended secondary prevention treatment.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2020) conducted a cohort in Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) (n=5,509). CAMI-NSTEMI risk score was evaluated on All-cause death at 24 months (C-statistic of the risk model in the derivation cohort) (C-statistic 0.83, 95% CI 0.81-0.85). The CAMI-NSTEMI risk score, incorporating 9 clinical variables, accurately predicted 24-month all-cause mortality in NSTEMI survivors with a C-statistic of 0.83.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: